The Tamesis
This comes as the population ages and chronic diseases increase.
According to DelveInsight, TAC-302 therapy is expected to capture the top market for underactive bladder syndrome (UAB) in China and seven other markets (7MM) by 2034.
TAC-302 is produced by Otsuka Holdings and is expected to be launched alongside Zeria Pharmaceutical’s ZG-802 and SFG Sciences’ SFG-02.
The study also said that emerging UAB drugs, aging global population, and rising prevalence of neurogenic and chronic diseases affecting bladder function will drive the growth of the UAB syndrome market.
Meanwhile, the company estimates that the total number of confirmed cases of segmented UAB cases, lower urinary tract symptoms (LUTS) in China and 7MM will be approximately 67 million by 2024.
UAB is a clinical condition characterized by reduced bladder muscle contractility, resulting in prolonged or incomplete bladder emptying.
DelveInsights predicts that the UAB market will grow at a compound annual growth rate (CAGR) of 22.1% from 2020 to 2034.
The forecast covers China, Japan, Germany, France, Italy, Spain, the United Kingdom and the United States.
The market size in 2024 will be US$107 million.
